NetworkNewsBreaks Archive - Page 2101 of 2221

FridayJul 28, 2017 1:09 pm

NetworkNewsBreaks – Windstream Holdings, Inc. (NASDAQ: WIN) Acquires Broadview Networks

Windstream Holdings (NASDAQ: WIN) has completed its acquisition of Broadview Networks Holdings, Inc. The company previously announced the $227.5 million all-cash transaction in April 2017. Additionally, the company announced that Brian Crotty, chief operating officer of Broadview, has been named president of the mid-market and small business division. Various other members of Broadview’s management team have also been added to the small business division. “The addition of Broadview advances our strategy to differentiate ourselves by delivering a truly superior customer experience using disruptive technologies,” Windstream president and chief executive officer Tony Thomas stated in the news release. To view the…

FridayJul 28, 2017 12:15 pm

NetworkNewsBreaks – Cesca Therapeutics, Inc. (NASDAQ: KOOL) Shares Tick Higher on Issuance of New Cellular Processing Methodology Patent

Cesca Therapeutics (NASDAQ: KOOL) shares are up 7% mid-day on news that SynGen, Inc. (whose cell processing assets were acquired by Cesca’s 80%-owned subsidiary ThermoGenesis Corp.) has been awarded a new patent entitled “Cell Separation Devices, Systems, and Methods” by the U.S. Patent and Trademark Office. The patent covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting processes. “This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems,” Cesca CEO Chris Xu stated in the news release. To…

FridayJul 28, 2017 12:12 pm

NetworkNewsBreaks – Algae Dynamics Corp. (ADYNF) Developing Potential Breakthrough Fortified Formulas to Boost Human Endocannabinoid System

As debates continue over the legalization of marijuana, many individuals who have never touched plant-derived cannabinoids (phytocannabinoids) do not realize that their bodies naturally produce endocannabinoids, which play an essential mediating role in various human physiologic systems. Recent studies have shown that the production of endocannabinoids is boosted by fatty acids, and Algae Dynamics (OTCQB: ADYNF) has begun developing fortified formulas of omega-3s and cannabis oil that could potentially boost the function of the human body’s endocannabinoid system. “The products under development by Algae Dynamics promise to pack a powerful therapeutic punch, combining the virtues of omega-3s and cannabinoids. Algae…

FridayJul 28, 2017 12:09 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (LXRP) Well-Positioned for Growth as First Mover in Canada’s Cannabinoid Market

Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste. “With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in…

FridayJul 28, 2017 9:22 am

NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment

Cannabis Wheaton Income Corp. (TSX.V: CBW) this morning announced that it has received approval from the TSX Venture Exchange to purchase $15 million of common shares of ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) at an agreed upon valuation of $2.25 per share. Per the update, this investment forms a portion of a larger phased investment by Cannabis Wheaton aimed at funding the construction of ABcann’s proposed 50,000 square foot addition to its Kimmett cannabis cultivation facility to be located in Napanee, Ontario. This morning’s announcement follows the two companies’ entry into a binding interim agreement on May 29, 2017,…

ThursdayJul 27, 2017 12:44 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: TYMI 48.15% – News: Uplisting to NASDAQ Capital Market on July 31 MIHI 30.67% – News: Appears on Mick Bazsuly Show and web cast part two NAKD 23.81% – News: Merger partner Bendon to acquire full ownership of FOH Online Corp. TRVB 23.33% – News: Posts Q2 2017 financial results MBRX 12.08% – News: Appoints new independent member to board of directors DRYS 10.58% – News: Names two new directors DTGI 10.42% – News:…

ThursdayJul 27, 2017 12:30 pm

NetworkNewsBreaks – Cerus Corp. (NASDAQ: CERS) Partners with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Shares of Cerus (NASDAQ: CERS) are up 15% following news of the company's agreement with the Central California Blood Center (CCBC). CCBC will manufacture for Cerus a pathogen-reduced cryoprecipitate (cryo), a blood product used in the control of bleeding associated with acquired fibrinogen deficiency. “Cryo is a natural extension to our current FDA-approved INTERCEPT Blood System for Plasma. Following approval of a proposed premarket approval (PMA) supplement, INTERCEPT Plasma may be further manufactured into cryoprecipitate, for which we plan to seek an extended 5-day post-thaw storage claim. Given today’s growing emphasis on, and use of, coagulation monitoring and fibrinogen supplementation…

ThursdayJul 27, 2017 12:27 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide

Interpace Diagnostics Group (NASDAQ: IDXG) has entered an agreement with Cigna to provide coverage of the company’s ThyGenX® test, effective immediately. Cigna is one of the largest national health plans in the United States, with 15 million members nationwide. This new agreement brings the number of individuals covered for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules to approximately 275 million patients nationwide. “Cigna’s coverage of ThyGenX represents further acceptance among major health plans of our molecular products for Thyroid cancer. We are pleased that Cigna has joined the growing list of health plans that cover ThyGenX and that their…

ThursdayJul 27, 2017 12:22 pm

NetworkNewsBreaks – Capricor Therapeutics, Inc. (NASDAQ: CAPR) Shares Surge on Details of Recent Meeting with FDA Regarding Intravenous CAP-1002

Capricor Therapeutics (NASDAQ: CAPR) shares are up 30% after the company said the U.S. FDA has indicated it is willing to accept the company’s proposal to use the Performance of the Upper Limb as the basis for the primary efficacy endpoint for clinical studies of CAP-1002 for the treatment of muscular dystrophy. Official minutes from the company's recent meeting with the regulatory agency also show support for submission of an Investigational New Drug (IND) application to clinically evaluate repeat intravenous administration of CAP-1002. "The FDA's response to our proposed clinical development plan supports our near-term objective of submitting an IND…

ThursdayJul 27, 2017 9:23 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Research Published in the European Journal of Pain

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the publication of company-sponsored research in the European Journal of Pain. The article, titled ‘Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation’, highlights results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship Program. “Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the 'holy grails' in the field of analgesia,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “This…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks